Gemcitabine hydrochloride is under clinical development by Fujifilm and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase II drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gemcitabine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemcitabine hydrochloride overview
Gemcitabine hydrochloride (FF-10832) is under development for the treatment of advanced solid tumors including pancreatic cancer, bladder cancer, urothelial cell cancer, non-small cell lung cancer and breast cancer. The drug candidate is a liposomal gemcitabine formulation administered through intravenous route. It acts by targeting DNA synthesis and ribonucleoside diphosphate reductase. It is developed based on nano-dispersion technology.
Fujifilm designs, manufactures, and markets healthcare solutions, material solutions, document solutions and imaging systems. The company offers document solutions such as office products, office printers, and allied production services and global services. Its major products include color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. Fujifilm also offers equipment and materials for medical systems, cell culture media and reagents, pharmaceuticals, cosmetics, and supplements. The company serves individual consumers and business enterprises. The company has business presence in the Americas, Europe, and Asia-Pacific. Fujifilm is headquartered in Minato-Ku, Tokyo, Japan.
For a complete picture of Gemcitabine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.